Fujifilm to Showcase Manufacturing Innovation and Leadership at CPHI 2026 Amid Three Award Shortlist Nominations
- Company leaders to headline speaking sessions on pharma’s structural shift, executing Europe’s biomanufacturing vision, and building pharmaceutical playbooks
- Maja Pedersen, President & Chief Operating Officer of FUJIFILM Biotechnologies, shortlisted for Woman of the Year, along with innovation recognition at the CPHI Pharma Awards
MILAN, ITALY – September 29. 2026 – FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced its participation in CPHI 2026, taking place October 6-8, 2026, in Milan, Italy. The company will bring together its senior leadership team for partnering meetings, networking, and a series of speaking sessions addressing the industry’s most pressing challenges, from pharma’s structural shift to executing Europe’s biomanufacturing vision.
This year’s presence comes as FUJIFILM Biotechnologies has been shortlisted for three CPHI Pharma Awards, highlighting the company’s momentum across leadership, innovation, and technical excellence:
- Woman of the Year – Maja Pedersen, President & Chief Operating Officer
- Innovation Catalyst – MaruX™ Continuous Manufacturing Platform
- API Development and Innovation – ShunzymeX™ Precision Purification Technology
“At CPHI, I look forward to hearing directly from our partners about what they need to move their programs forward,” said Maja Pedersen, president and chief operating officer of FUJIFILM Biotechnologies. “Our expanding global manufacturing network gives us more ways to support them. Our focus is on making that network work as one: kojoX™. Bringing new capacity online, delivering reliably, and giving partners the visibility they need to plan with confidence.”
FUJIFILM Biotechnologies’ speaker lineup at CPHI 2026 will feature:
Christiane Bardroff | Chief Business Officer
Pharma’s Structural Shift: What’s Reshaping Global Priorities
October 6 | 10:55 – 11:50 a.m. CEST
This panel will explore how leaders are responding to macro shifts in the industry across economic pressures, geopolitics, and rapid science/technological advances, and how it is reshaping manufacturing strategies.
Christian Houborg | General Manager & Senior Vice President, FUJIFILM Biotechnologies Denmark
Beyond the Blueprint: Executing Europe’s Bio-Manufacturing Vision
October 7 | 11:35 a.m. – 12:20 p.m. CEST
This panel will examine the practical execution challenges of the Biotech Act II legislative framework and how companies are navigating regulatory pathways, structuring partnerships, and building manufacturing capability under the new policy environment—and where structural barriers persist despite legislative intent.
Jonathan Haigh | Senior Vice President & UK Site Head, FUJIFILM Biotechnologies
Building a BsAb CMC Playbook: Decision Frameworks, Risks, and Readiness
October 7 | 1:45 – 2:10 p.m. CEST
Presented in the Next Gen Bio Theatre, this session will examine a practical framework for bispecific antibody development, combining predict-first bioinformatics and process optimization strategies to enable a more efficient path from development to commercial launch.
Attendees can meet with Fujifilm at CPHI 2026 in Milan at Booth #8A2 to discuss end-to-end CDMO services, advanced biologics manufacturing, and partnership opportunities. Schedule a meeting using this form.
For more information about Fujifilm’s presence at CPHI, please visit: https://fujifilmbiotechnologies.fujifilm.com/about/events/cphi-2026/
## ENDS ##
About FUJIFILM Biotechnologies
FUJIFILM Biotechnologies, made up of several legal subsidiaries of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines and advanced therapies. With over 30 years of experience, the Company specializes in developing and manufacturing biopharmaceuticals using microbial, mammalian, and host/virus systems. With over 5,000 employees, FUJIFILM Biotechnologies operates an integrated network with major facilities in the United States, the United Kingdom, and Denmark. Under its kojoX philosophy, the Company aims to harmonize processes, procedures, systems, data, facility designs and equipment across its global manufacturing network to increase speed, while ensuring consistency, quality, scalability, and supply chain resilience. FUJIFILM Biotechnologies offers comprehensive services, ranging from proprietary cell line development, to process and analytical development, and through to clinical and commercial manufacturing. For more information, go to: fujifilmbiotechnologies.fujifilm.com.
About FUJIFILM Holdings Corporation
FUJIFILM Corporation is a subsidiary of FUJIFILM Holdings Corporation. Founded in 1934, FUJIFILM Holdings Corporation, headquartered in Tokyo, Japan, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of Healthcare, Electronics, Business Innovation and Imaging with over 70,000 employees. Guided and united by its Group Purpose of “Giving our world more smiles,” the company addresses social challenges and creates a positive impact on society through products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, Fujifilm aspires to continue its evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (24.8 billion EUR at an exchange rate of 161 JPY/EUR). For more information visit: www.fujifilmholdings.com.
Media Contact:
Christine Jackman
FUJIFILM Biotechnologies
christine.jackman@fujifilm.com
+1-914-261-4959